The Lancet Rheumatology Publishes Additional Findings on Tocilizumab, Fueled by Real-World Data
A recent observational study using real world data shows promising results from using tocilizumab in patients with severe COVID-19. According to study co-author Shivam Mathura, “While these results need to be further validated through clinical trials, we are thrilled to provide early insights to those in the field as we continue to fight this pandemic.”
COTA Featured in BioCentury – Real World Data’s Power to Increase Racial Diversity in Clinical Research
COTA’s Chief Medical Officer, Dr. C.K. Wang spoke with BioCentury to help further the conversation around the role of RWD in increasing racial diversity in clinical research.
Health Evolution Features COTA’s Advancements With RWE & COVID-19
Along with COTA’s data analytics expertise, Hackensack Meridian Health has been pioneering some of the early work to understand COVID-19. Stuart Goldberg, MD, chief of the Division of Outcomes and Value Research at the John Theurer Cancer Center and Mike Doyle, CEO of COTA, recently spoke with Health Evolution about the findings so far, and how we continue to learn from existing patients.
How Real-World Data Is Helping FDA Address the COVID-19 Pandemic
The FDA’s Dr. Amy Abernethy describes how the agency and the scientific community are using real-world data to respond to COVID-19.
COTA Featured in OncLive – Data Analytics Making Inroads Into Oncology Practices
Around this growing interest and adoption, COTA’s chief medical officer, Dr. C.K. Wang, recently spoke with OncLive about how COTA’s Real World Analytics platform helps cancer centers correlate care patterns with outcomes.
COTA’s Mike Doyle Reflects on COVID-19 as a CEO & Health Data Veteran
In two recent articles, COTA CEO Mike Doyle reflects on how the pandemic is challenging leaders to be flexible and, specifically in healthcare, how data companies can be doing more.
Does Using RWE in COVID-19 Research Eliminate the Barrier of Time? Two Data Scientists Explain
To further explain COTA’s in-depth analysis and research methods from this ongoing work, Kathryn Tanenbaum, Senior Manager of Operations at COTA spoke with two of our data experts leading COTA’s analysis, Eric Hansen, director of analytics, and Shivam Mathura, director of product and strategy.
COTA Supports FDA Assessment of Real-World Data through Membership in COVID-19 Evidence Accelerator
Leveraging its past knowledge of real-world evidence applications and learnings, COTA has joined the COVID-19 Evidence Accelerator program, a joint initiative of Friends of Cancer Research (Friends) and the Reagan-Udall Foundation for the Food and Drug Administration. Through this initiative, COTA is delivering findings from its observational, real-world studies using data from over 3,000 patients hospitalized with COVID-19 within the Hackensack Meridian Health network.
COTA, Inc. Announces Participation in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program and DIA 2020 Virtual Global Annual Meeting
COTA, Inc., is pleased to announce its involvement and participation in two industry leading conferences – the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program and the DIA 2020 Virtual Global Annual Meeting. Collectively, the involvement at these two premier events further underscores the importance of RWD’s role in clinical research and oncology care delivery.
2020 MedTech Breakthrough Awards Recognize COTA as the Best Overall Medical Data Solution Provider
COTA, Inc. is pleased to announce that MedTech Breakthrough has named COTA as a winner in the fourth annual MedTech Breakthrough Awards program for the “Best Overall Medical Data Solution Provider” award.
